The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...
The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback